Valued to be $10.5 Billion by 2026, RNA Analysis / Transcriptomics Slated for Robust Growth Worldwide

BY PR Newswire | ECONOMIC | 11/16/21 10:40 AM EST

SAN FRANCISCO, Nov. 16, 2021 /PRNewswire/ --?A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled?"RNA Analysis / Transcriptomics - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.

RNA Analysis / Transcriptomics

Edition:?7;?Released:?October 2021
Executive Pool:?2833
Companies:?44 - Players covered include Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; CD Genomics; F. Hoffmann-La Roche Ltd.; GenXPro GmbH; Illumina, Inc.; LC Sciences; Merck KGaA; Qiagen N.V.; Sequentia Biotech SL; Thermo Fisher Scientific Inc. and Others.
Coverage:?All major geographies and key segments
Segments:?Product (Reagents / Consumables, Instruments, Services, Software); Technology (Polymerase Chain Reaction, Sequencing, Microarray, RNA Interference); Application (Drug Discovery, Toxicogenomics, Clinical Diagnostics, Comparative Transcriptomics)
Geographies:?World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Complimentary Project Preview -?This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass? Platform which offers thousands of data bytes without an obligation to purchase our report.?Preview Registry


Global RNA Analysis / Transcriptomics Market to Reach US$10.5 Billion by the Year 2026
Transcriptomics is the study of the RNA transcripts set produced by the organism's genome. Transcriptome analysis enables researchers to understand DNA's sequence as well as its functioning. The gene expression patterns' increased demand for specific genes, various assay technologies, quantification of multiplexed RNA, increased requirement for genetic testing and personalized medicine, rise in genetic variation and genetic mutation incidences boost the transcriptomics technologies market demand. Additionally, continuous technological developments in products increased commercialization, and increasing disease cases such as hepatitis B, diabetes, and cancer, too, propel the transcriptomics technologies market growth. Pharmaceutical and biotechnology companies' R&D funding, increased demand for compact and reliable products, too, are the other key factors anticipated to drive market growth. Innovations and new product launches are also projected to fuel the growth over the analysis period. For instance, NuGEN Technologies, Inc.'s Trio RNA-Seq, which provides a highly sensitive end-to-end transcriptomics solution, is ideal for use in low abundance transcripts applications. The innovative Trio RNA-Seq technique integrates three powerful technologies, including single primer isothermal amplification (SPIA); AnyDeplete, for use in high sensitivity ribonucleic acid (RNA) analysis; and DimerFree.

Amid the COVID-19 crisis, the global market for RNA Analysis / Transcriptomics estimated at US$4.7 Billion in the year 2020, is projected to reach a revised size of US$10.5 Billion by 2026, growing at a CAGR of 14.1% over the analysis period. Reagents / Consumables, one of the segments analyzed in the report, is projected to grow at a 15.4% CAGR to reach US$5.9 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Instruments segment is readjusted to a revised 12.5% CAGR for the next 7-year period. This segment currently accounts for a 30.1% share of the global RNA Analysis / Transcriptomics market.

The U.S. Market is Estimated at $2.2 Billion in 2021, While China is Forecast to Reach $891.5 Million by 2026
The RNA Analysis / Transcriptomics market in the U.S. is estimated at US$2.2 Billion in the year 2021. The country currently accounts for a 39.34% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$891.5 Million in the year 2026 trailing a CAGR of 15.6% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.9% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR while Rest of European market (as defined in the study) will reach US$1 Billion by the end of the analysis period. North America represents the most dominant region because of the presence of a large number of biotech companies having well-established infrastructure and state-of-the-art technological platforms. Growing opportunities, increasing healthcare expenditure, and the introduction of government initiatives are the other factors driving market growth. Additionally, the sustained increase in transcriptomics-related research and development investments by the private sector is enabling the regional market players to develop targeted therapeutics.

Services Segment to Reach $2 Billion by 2026
In the global Services segment, USA, Canada, Japan, China and Europe will drive the 14.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$744.8 Million in the year 2020 will reach a projected size of US$1.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$130.8 Million by the year 2026. More

MarketGlass? Platform
Our MarketGlass? Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website or via our just released mobile application on?iOS?or?Android

About Global Industry Analysts, Inc. & StrategyR?
Global Industry Analysts, Inc., ( is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.

Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966

Join Our Expert Panel

Connect With Us on LinkedIn

Follow Us on Twitter

Journalists & Media

Cision View original content to download multimedia:

SOURCE Global Industry Analysts, Inc.

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.